Saturday 17 October 2026
Export MEDS’s income statement to Excel — free account
DataMeds AI, Inc
MEDS Healthcare Pharmaceutical Retailers
DataMeds AI, Inc’s revenue for fiscal 2025 (year ended December 2025) was $23.3 million, up 28.7% from fiscal 2024. In the quarter to June 2026, revenue fell 77.2%, EPS fell 29.6%, free cash flow fell 41.9% and total debt fell 15.4%, each against the same quarter a year earlier.
2.63
0.22
−7.72%
Follow MEDS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+7 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.94 | 1.22 | 0.72 | 0.99 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(58.11) | (4.51) | (2.94) | (2.76) | |
P/B ratio |
9.73 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.66 | 2.22 | 2.22 | 3.14 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(12.61) | (4.78) | (2.41) | (1.84) | |
EV/FCF |
(12.00) | (4.42) | (2.27) | (1.72) | |
Quick Ratio |
0.16 | 0.04 | 0.03 | 0.09 | |
Current Ratio |
0.39 | 0.09 | 0.09 | 0.14 | |
Net Debt/EBITDA |
(0.81) | (1.89) | (5.07) | (2.81) | |
Debt/Assets |
54.62% | 77.11% | 70.38% | 60.15% | |
Debt/Equity |
4.25 | (1.89) | (1.41) | (1.01) | |
Asset Turnover |
1.28 | 0.53 | 0.32 | 0.18 | |
Operating CF/Net income |
0.03 | 0.23 | 0.44 | 0.16 | |
Capex/Depreciation |
(0.18) | (0.02) | (0.11) | (0.20) | |
Interest Coverage |
(22.13) | (28.95) | (2.90) | (4.70) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,028.13% | 247.76% | 373.74% | 402.87% | |
Intangible Assets out of Total Assets |
0.66 | 0.80 | 0.80 | 0.73 | |
Share Based Compensation of Revenue |
854.00% | 21.29% | 87.06% | 67.68% | |
Graham Net Nets |
(0.50) | (1.41) | (4.22) | (5.84) | |
Graham Number |
0.00 | 119.18 | 84.90 | 88.67 | |
Earnings Yield |
(144.55%) | (360.00%) | (927.08%) | (1,488.06%) | |
Free Cash Flow Yield |
(11.44%) | (41.33%) | (136.75%) | (183.67%) | |
Revenue per Share |
2.03 | 1.18 | 0.75 | 0.69 | |
Operating CF per Share |
(0.76) | (4.43) | (1.63) | (1.12) | |
Capex per Share |
(0.15) | (0.18) | (0.10) | (0.09) | |
Free Cash Flow per Share |
(0.91) | (4.61) | (1.73) | (1.22) | |
Cash per Share |
2.84 | 0.03 | 0.02 | 0.95 | |
Shareholders Equity per Share |
4.56 | (8.77) | (7.20) | (7.58) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.56 | (8.77) | (7.20) | (7.58) | |
Free Cash Flow |
(1.36) | (6.55) | (3.62) | (3.14) | |
Working Capital |
(19.92) | (26.96) | (29.44) | (33.78) | |
Capital Expenditures |
(0.22) | (0.26) | (0.21) | (0.24) | |
Net Current Asset Value |
(33.18) | (40.09) | (42.43) | (46.63) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.15 | 0.13 | 0.14 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.72 | 2.44 | 2.48 | 2.60 | |
Average Payables |
5.74 | 9.01 | 10.11 | 11.06 | |
Average Inventory |
— | 5.58 | 5.72 | 5.27 | |
Average Assets |
26.56 | 43.90 | 44.10 | 43.49 | |
Average Common Equity |
1.94 | (2.86) | (5.29) | (9.30) |
Columns are period end dates